首页> 外文期刊>British Journal of Cancer >Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood
【24h】

Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood

机译:黑色素瘤抑制活性(MIA)mRNA并非仅在黑色素瘤细胞中转录:各种细胞类型和外周血中存在低水平的MIA mRNA

获取原文
           

摘要

The detection of minimal amounts of melanoma cells by tyrosinase reverse transcription polymerase chain reaction (RT-PCR) is seriously hampered by false negative reports in blood of melanoma patients with disseminated melanoma. Therefore, additional assays which make use of multiple melanoma markers are needed. It has been shown that introduction of multiple markers increases the sensitivity of detection. Melanoma inhibitory activity (MIA) is one such melanoma-specific candidate gene. To test the specificity of MIA PCR, we performed 30 and 60 cycles of PCR with two different sets of MIA specific primers on 19 melanoma and 16 non-melanoma cell lines. MIA mRNA was detected in 16 out of 19 melanoma cell lines and in seven out of 16 non-melanoma cell lines after 30 cycles of PCR. However, MIA mRNA could be detected in all cell lines after 60 cycles of PCR. Also, in 14 out of 14 blood samples of melanoma patients, five out of six blood samples of non-melanoma patients and in seven out of seven blood samples of healthy volunteers, MIA mRNA was detected after 60 cycles of PCR, whereas no MIA PCR product could be detected in any of the blood samples after 30 cycles of PCR. We conclude that low levels of MIA transcripts are present in various normal and neoplastic cell types. Therefore, MIA is not a suitable marker gene to facilitate the detection of minimal amounts of melanoma cells in blood or in target organs of the metastatic process.
机译:酪氨酸酶逆转录聚合酶链反应(RT-PCR)检测最小量的黑色素瘤细胞受到散布黑色素瘤患者血液中假阴性报告的严重阻碍。因此,需要利用多种黑色素瘤标记物的其他测定。已经表明引入多个标记物可以提高检测的灵敏度。黑色素瘤抑制活性(MIA)就是这样一种黑色素瘤特异性候选基因。为了测试MIA PCR的特异性,我们在19个黑素瘤和16个非黑素瘤细胞系上用两组不同的MIA特异性引物进行了30和60个循环的PCR。经过30个PCR循环后,在19个黑色素瘤细胞系中的16个和16个非黑色素瘤细胞系中的7个中检测到MIA mRNA。但是,经过60个PCR循环后,可以在所有细胞系中检测到MIA mRNA。此外,在黑色素瘤患者的14份血液样本中的14份,非黑色素瘤患者的6份血液样本中的5份和健康志愿者的7份血液样本中的7份,在60个PCR循环后检测到MIA mRNA,而没有MIA PCR经过30个PCR循环后,可以在任何血样中检测到这种产物。我们得出结论,在各种正常和赘生性细胞类型中均存在低水平的MIA转录本。因此,MIA不是适合于检测血液或转移过程的靶器官中最小量黑色素瘤细胞的合适标记基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号